Shares of Silence Therapeutics plc (LON:SLN – Get Free Report) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 535 ($6.69) and traded as low as GBX 512 ($6.40). Silence Therapeutics shares last traded at GBX 535 ($6.69), with a volume of 913,528 shares trading hands.
Silence Therapeutics Trading Down 0.9 %
The company’s fifty day moving average is GBX 535 and its 200-day moving average is GBX 535. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.52 and a quick ratio of 4.36. The company has a market capitalization of £480.35 million and a PE ratio of -11.01.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Featured Stories
- Five stocks we like better than Silence Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Micron Stock Under $100: Seize the AI-Driven Upside
- EV Stocks and How to Profit from Them
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- Why Invest in 5G? How to Invest in 5G Stocks
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
